Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam and alfentanil sedation regimens for elderly patients undergoing diagnostic bronchoscopy
ChiCTR2400085680Phase 4Not yet recruiting
- Sponsor
- Beilun District People's Hospital
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam, alfentanil, midazolam and propofol in bronchopulmonary diseases (3 arms), sponsored by Beilun District People's Hospital. Primary endpoints: VAS score of cough response and Sedation success rate. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
remimazolamalfentanilmidazolampropofol
03
Conditions
bronchopulmonary diseases
Beyond the preview
Go deeper on ChiCTR2400085680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085680.